Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD in children, adolescents, and adults. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
तुलना करने के लिए मीट्रिक्स | CING | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधCINGपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −1.7x | −1.6x | −0.6x | |
PEG अनुपात | −0.02 | −0.04 | 0.00 | |
क़ीमत/बुक | 10.2x | 1.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 2.2x | 3.4x | |
अपसाइड (विश्लेषक लक्ष्य) | 329.8% | 242.0% | 40.3% | |
उचित मूल्य अपसाइड | अनलॉक करें | 12.8% | 4.8% | अनलॉक करें |